- Home
- IGMS vs FFA Comparison
IGMS vs FFA Comparison
Compare IGMS & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- FFA
- Stock Information
- Founded
- IGMS 1993
- FFA 2004
- Country
- IGMS United States
- FFA United States
- Employees
- IGMS N/A
- FFA N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- FFA Investment Managers
- Sector
- IGMS Health Care
- FFA Finance
- Exchange
- IGMS Nasdaq
- FFA Nasdaq
- Market Cap
- IGMS 348.5M
- FFA 411.2M
- IPO Year
- IGMS 2019
- FFA N/A
- Fundamental
- Price
- IGMS $1.77
- FFA $20.85
- Analyst Decision
- IGMS Hold
- FFA
- Analyst Count
- IGMS 8
- FFA 0
- Target Price
- IGMS $6.14
- FFA N/A
- AVG Volume (30 Days)
- IGMS 779.9K
- FFA 26.1K
- Earning Date
- IGMS 03-06-2025
- FFA 01-01-0001
- Dividend Yield
- IGMS N/A
- FFA 6.72%
- EPS Growth
- IGMS N/A
- FFA N/A
- EPS
- IGMS N/A
- FFA N/A
- Revenue
- IGMS $2,918,000.00
- FFA N/A
- Revenue This Year
- IGMS $23.57
- FFA N/A
- Revenue Next Year
- IGMS $192.36
- FFA N/A
- P/E Ratio
- IGMS N/A
- FFA N/A
- Revenue Growth
- IGMS 57.64
- FFA N/A
- 52 Week Low
- IGMS $1.59
- FFA $15.84
- 52 Week High
- IGMS $22.50
- FFA $19.30
- Technical
- Relative Strength Index (RSI)
- IGMS 19.54
- FFA 57.47
- Support Level
- IGMS $1.59
- FFA $20.03
- Resistance Level
- IGMS $2.06
- FFA $20.63
- Average True Range (ATR)
- IGMS 0.45
- FFA 0.29
- MACD
- IGMS -0.30
- FFA 0.03
- Stochastic Oscillator
- IGMS 3.27
- FFA 92.13
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.